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Purpose: To study the determinants and accuracy of peak oxygen uptake (VO2) to predict the 
outcome of patients with heart failure (HF) in the current era of disease modifying therapy. 
 
Methods: We studied 282 patients with HF who consecutively underwent ergospirometry for 
prognostic stratification from 2009 to 2015 in a single center. Baseline variables independently 
associated with peak VO2 were identified by means of lineal regression. Survival was assessed by 
means of the Kaplan-Meier method and Cox ́ s regression. 
 
Results: Mean age of studied patients was 52.7 years; 24% were women, 42% had ischemic heart 
disease and 74% had reduced LVEF (<0.40). NYHA III or IV class was present in 36% cases. 
92% patients were on beta-blockers, 79% on ACEI/ARBs and 70% on MRAs. Mean VO2 was 
19.6±5.2 ml/kg/min. In multivariable linear regression, age (p<0.001), NT-pro-BNP (p<0.001), 
body mass index (p<0.001), and female sex (p=0.027) were independently associated with lower 
VO2, while TAPSE (p<0.001) was independently associated with higher VO2. A peak VO2 < 14 
ml/kg/min was associated with significantly higher risk of the composite outcome death, heart 
transplantation or need for mechanical circulatory support during follow-up (HR 2.38, 95% CI 
1.10–5.26, p=0.027). 
 
Conclusions: Peak VO2 retains a significant prognostic value in the current era of HF disease 
modifying therapy. In our study, age, female gender, body mass index, NTproBNP and TAPSE 
were identified as independent clinical determinants of peak VO2. 
